Pfizer Inc. (PFE) announced new data on PRISTIQ (desvenlafaxine) Extended Release Tablets 50 mg/day for the treatment of major depressive disorder, or MDD, in adults, including a long-term relapse prevention study.
According to the company, these new data, and data from a study in peri- and post-menopausal women with MDD, add to the existing efficacy and safety profile of PRISTIQ for the treatment of MDD. Lastly, new data also provide information regarding the discontinuation of PRISTIQ 50 mg/day for the treatment of adults with MDD.
These new PRISTIQ 50 mg/day data focus on key factors - efficacy, safety, long-term use and discontinuation - that clinicians often consider when assessing antidepressants for the treatment of MDD.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org